Patent ID: 8637084

Claim:
A method for treating a living individual with epithelial cancer, the epithelial cancer being positive for a cancer-specific membrane antigen expressed in epithelial cancer cells and positive for a KLRG1 ligand, the method comprising: selectively reducing KLRG1-positive immunocytes in the peripheral blood of the living individual with epithelial cancer ex vivo; administering to the living individual the peripheral blood from which the KLRG1-positive immunocytes have been selectively reduced, wherein the adsorption percentage of the KLRG1-positive immunocytes (B)/the adsorption percentage of the KLRG1-negative immunocytes (A) is >2; and administering to the living individual a therapeutic agent for cancer comprising an antibody reacting with the cancer-specific membrane antigen and having antibody-dependent cell cytotoxicity.